Early indicators of exposure to biological threat agents using host gene profiles in peripheral blood mononuclear cells

<p>Abstract</p> <p>Background</p> <p>Effective prophylaxis and treatment for infections caused by biological threat agents (BTA) rely upon early diagnosis and rapid initiation of therapy. Most methods for identifying pathogens in body fluids and tissues require that the pathogen proliferate to detectable and dangerous levels, thereby delaying diagnosis and treatment, especially during the prelatent stages when symptoms for most BTA are indistinguishable flu-like signs.</p> <p>Methods</p> <p>To detect exposures to the various pathogens more rapidly, especially during these early stages, we evaluated a suite of host responses to biological threat agents using global gene expression profiling on complementary DNA arrays.</p> <p>Results</p> <p>We found that certain gene expression patterns were unique to each pathogen and that other gene changes occurred in response to multiple agents, perhaps relating to the eventual course of illness. Nonhuman primates were exposed to some pathogens and the <it>in vitro</it> and <it>in vivo</it> findings were compared. We found major gene expression changes at the earliest times tested post exposure to aerosolized <it>B. anthracis </it>spores and 30 min post exposure to a bacterial toxin.</p> <p>Conclusion</p> <p>Host gene expression patterns have the potential to serve as diagnostic markers or predict the course of impending illness and may lead to new stage-appropriate therapeutic strategies to ameliorate the devastating effects of exposure to biothreat agents.</p

INTRATRACHEAL ADMINISTRATION OF IMMUNOGLOBULINS FOR THE PREVENTION OF PSEUDOMONAS AERUGINOSA PNEUMONIA IN MICE

This study describes a unique approach to the prevention of gram negative bacterial pneumonia. It dealt with the following topics: Establishment of pneumonia in mice by intratracheal inoculation with a mucoid strain of Pseudomonas aeruginosa; successful prevention of pneumonia and death in infected mice by prior intratracheal instillation of antiserum and immune globulins; and characterization of the protective activity of immune globulins by histopathological observation, lung lavage, and opsonophagocytic assays. Intratracheal inoculation was accomplished using a blunt tipped feeding needle inserted through the larynx. Instillation of 5 x 10(\u278) colony forming units of a cystic fibrosis-derived mucoid strain of P. aeruginosa (PA 1433) produced an acute pneumonia in all mice within 24 hours. The pneumonia was non-bacteremic, and infected animals died within 36-48 hours after inoculation. Rabbit antiserum, produced against a heat-killed whole cell PA 1433 bacterin, and fractionated globulins, were effective in preventing morbidity and mortality when given intratracheally 1, 3, or 5 days before bacterial challenge. The greatest degree of protection, measured by survival and bacterial clearance studies, was seen when globulins were administered 3 days before infection. Intratracheal administration of normal rabbit serum afforded little or no protection against subsequent bacterial challenge. Analysis of lung lavage samples taken after administration of globulins revealed a marked influx of neutrophils after 1 day in mice receiving both normal and immune globulins. Three days after instillation, there were more macrophages in lavage samples taken from mice receiving immune globulins. Using in vitro opsonophagocytic assays, both alveolar macrophages and neutrophils were shown to be effective in killing PA 1433 in the presence of immune globulins. Thus, the mechanism for the observed protective activity of immune globulins is likely due to recruitment of phagocytic cells into the lung, and opsonization of the bacteria for subsequent phagocytosis

Oral Vaccination with Brucella melitensis WR201 Protects Mice against Intranasal Challenge with Virulent Brucella melitensis 16M

Human brucellosis can be acquired from infected animal tissues by ingestion, inhalation, or contamination of conjunctiva or traumatized skin by infected animal products. In addition, Brucella is recognized as a biowarfare threat agent. Although a vaccine to protect humans from natural or deliberate infection could be useful, vaccines presently used in animals are unsuitable for human use. We tested orally administered live, attenuated, purine auxotrophic B. melitensis WR201 bacteria for their ability to elicit cellular and humoral immune responses and to protect mice against intranasal challenge with B. melitensis 16M bacteria. Immunized mice made serum antibody to lipopolysaccharide and non-O-polysaccharide antigens. Splenocytes from immunized animals released interleukin-2 and gamma interferon when grown in cultures with Brucella antigens. Immunization led to protection from disseminated infection and enhanced clearance of the challenge inoculum from the lungs. Optimal protection required administration of live bacteria, was related to immunizing dose, and was enhanced by booster immunization. These results establish the usefulness of oral vaccination against respiratory challenge with virulent Brucella and suggest that WR201 should be further investigated as a vaccine to prevent human brucellosis

A Porcine Wound Model of Acinetobacter baumannii Infection.

Objective: To better understand Acinetobacter baumannii pathogenesis and to advance drug discovery against this pathogen, we developed a porcine, full-thickness, excisional, monospecies infection wound model. Approach: The research was facilitated with AB5075, a previously characterized, extensively drug-resistant A. baumannii isolate. The model requires cyclophosphamide-induced neutropenia to establish a skin and soft tissue infection (SSTI) that persists beyond 7 days. Multiple, 12-mm-diameter full-thickness wounds were created in the skin overlying the cervical and thoracic dorsum. Wound beds were inoculated with 5.0 × 104 colony-forming units (CFU) and covered with dressing. Results: A. baumannii was observed in the wound bed and on the dressing in what appeared to be biofilm. When bacterial burdens were measured, proliferation to at least 106 CFU/g (log106) wound tissue was observed. Infection was further characterized by scanning electron microscopy (SEM) and peptide nucleic acid fluorescence in situ hybridization (PNA-FISH) staining. To validate as a treatment model, polymyxin B was applied topically to a subset of infected wounds every 2 days. Then, the treated and untreated wounds were compared using multiple quantitative and qualitative techniques to include gross pathology, CFU burden, histopathology, PNA-FISH, and SEM. Innovation: This is the first study to use A. baumannii in a porcine model as the sole infectious agent. Conclusion: The porcine model allows for an additional preclinical assessment of antibacterial candidates that show promise against A. baumannii in rodent models, further evaluating safety and efficacy, and serve as a large animal in preclinical assessment for the treatment of SSTI